Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
venous thrombosis (VT) and electrically mediated carotid arterial thrombosis (ECAT) rabbit models
ClH/c1-2-5(7)3-4-6(8)9
as well as A431 and MDA-468 tumor cells with IC50 of 61 nM
Rift Valley fever virus (RVFV)
sourced from Glycine max with antioxidant
Evacetrapib Size:Solid 2 mg venous thrombosis (VT) and electricallyEvacetrapib, also known as LY2484595, is a CETP inhibitor currently under development by Eli Lilly & Company. LY2484595 inhibits cholesterylester transfer protein, which transfers and thereby increases high density lipoprotein and lowers low density lipoprotein. It is thought that modifying lipoprotein levels modifies the risk of cardiovascular disease. The first CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone